Valuation: Indivior Pharmaceuticals, Inc.

Capitalization 4.82B 4.09B 3.74B 3.53B 6.59B 455B 6.65B 44.42B 17.32B 218B 18.07B 17.69B 754B P/E ratio 2026 *
12.4x
P/E ratio 2027 * 11.5x
Enterprise value 4.87B 4.14B 3.79B 3.57B 6.67B 460B 6.73B 44.92B 17.51B 221B 18.27B 17.89B 763B EV / Sales 2026 *
3.87x
EV / Sales 2027 * 3.43x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
1 day-0.25%
1 week+4.89%
Current month+7.40%
1 month+22.25%
3 months+16.66%
6 months+26.04%
Current year+10.09%
1 week 38.19
Extreme 38.19
41
1 month 30.11
Extreme 30.11
41
Current year 27.68
Extreme 27.68
41
1 year 10.63
Extreme 10.63
41
3 years 7.33
Extreme 7.33
41
5 years 7.33
Extreme 7.33
41
10 years 1.75
Extreme 1.75
41
Change 5d. change 1-year change 3-years change Capi.($)
-0.25%+4.89%+256.50%+104.50% 4.82B
-2.72%-1.54%+29.12%+121.40% 846B
-0.53%-2.58%+43.51%+37.42% 533B
-0.57%-2.44%+9.18%+37.27% 356B
-0.94%-0.97%+22.40%+11.18% 324B
+0.23%-1.24%+30.31%+12.00% 282B
+0.05%-2.19%+24.69%+21.29% 278B
-0.82%-0.70%+46.61%-5.15% 275B
-1.76%+4.42%-34.66%-49.15% 203B
+0.79%+0.57%+24.76%+41.49% 179B
Average -0.65%-0.18%+45.24%+33.23% 328.06B
Weighted average by Cap. -1.05%-1.26%+25.97%+44.32%

Financials

2026 *2027 *
Net sales 1.26B 1.07B 978M 923M 1.72B 119B 1.74B 11.6B 4.52B 57.06B 4.72B 4.62B 197B 1.29B 1.09B 1B 945M 1.76B 122B 1.78B 11.87B 4.63B 58.4B 4.83B 4.73B 202B
Net income 414M 352M 322M 304M 567M 39.14B 572M 3.82B 1.49B 18.8B 1.55B 1.52B 64.91B 455M 386M 354M 334M 623M 42.96B 628M 4.2B 1.64B 20.64B 1.71B 1.67B 71.25B
Net Debt 54.5M 46.3M 42.38M 40M 74.61M 5.15B 75.26M 503M 196M 2.47B 204M 200M 8.54B -403M -343M -314M -296M -552M -38.1B -557M -3.72B -1.45B -18.3B -1.51B -1.48B -63.18B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
833
Date Price Change Volume
08/05/26 39.50 $ -0.25% 2,480,135
07/05/26 39.60 $ -2.49% 3,516,226
06/05/26 40.61 $ +2.58% 2,823,715
05/05/26 39.59 $ +1.56% 2,757,078
04/05/26 38.98 $ +3.51% 4,510,284
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
39.50USD
Average target price
51.50USD
Spread / Average Target
+30.38%

Quarterly revenue - Rate of surprise